• Home
  • About us
  • Partners
  • News
  • NEWS
  • Contact us
www.amlvaccin.eu
  • Home
  • About Us
  • Partners
  • News
  • NEWS
  • Contact Us
  • AML-VACCiN
    is developing a novel treatment strategy for the rare disease Acute Myeoloid Leukaemia

ABOUT AML-VACCiN

AML-VACCiN is developing a novel treatment strategy for the rare disease Acute Myeoloid Leukaemia (AML).

Aim of the project

AML is a deadly rare disease that affects both children and adults. Approximately 55% of younger AML patients and 85% of older patients ( >60 years of age), will relapse and die within 2 years. This is attributed to subclinical levels of leukaemic cells that remain or become resistent to chemotherapy, which is referred to as Minimal Residual Disease (MRD). Immunotherapy has great potential for treating MRD and dendritic cell (DC) therapy is at the forefront of immunotherapy.

Consortium

AML-VACCiN is the orchestrated action of three innovative companies and internationally renowned top medical scientists representing nine European medical institutes. In line with the IRDiRC objectives, this public-private consortium can bring a powerful AML-vaccine very close to clinical practice.

Aim of the project

The AML-VACCiN consortium takes this to the next level through clinical development of a highly innovative DC vaccine – DCP-001. The aim is to vaccinate post-remission AML patients, eradicate MRD and effectively reduce the risk of relapse. DCP-001 is designated as an orphan medicinal product in the EU and a Phase I/IIa study has been completed with DCP-001. The AML-VACCiN consortium will advance the clinical development of this vaccine further, from early-stage (current status) towards proof of concept for safety and efficacy in a Phase IIb clinical study. In addition, the study will be accompanied by an extensive immune-monitoring program so as to enable evaluation of clinical responses in relation to immunological responses. The deliverables resulting from this project can be used to assemble a data package to apply for conditional approval in Europe.

Project Facts

Grant agreement number:
667713

EC contribution:
€ 6.001.482

Duration:
48 months

Starting date:
January 2016

Partners

VUmc
The Netherlands

vumc

DCPrime BV
Netherlands

DCPrime_BV-logo

EUFETS
Germany

eufets-gmbh

Immatics GmbH
Germany

immatcis

University of Bergen
Norway

university-of-bergen

UMCG
The Netherlands

umcg_logo

Universitaetsklinikum Bonn
Germany

universitatsklinikum-bonn

Helse Bergen HF Haukeland University Hospital Norway

helse-bergen-hf

Universitaetsmedizin der johannes gutenberg Universitaet Mainz Germany

johannes-gutenberg-universitat-mainz

Technische Universitaet Dresden
Germany

technische-universitat-dresden

Uppsala Universitet
Sweden

uppsala-universitat

Helsingin Yliopisto
Finland

helsingin-yliopisto

Accelovance

Accelovance

Contact details

Coordinator address – VUmc
De Boelelaan 1117
1081 HV Amsterdam

mobile +31(0)6 46853981
phone +31 (0)88 495 20 00

Scientific Coordinator
Erik Manting, PhD
CEO DCPrime
Galileiweg 8
2333 BD Leiden
The Netherlands

T : +31 (0)71 – 332 26 20
E: e.manting@dcprime.nl
www.dcprime.nl

  • PROJECT INFO

    This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 667713. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.